Fed. Circ. Backs PTAB Ax Of J&J Prostate Cancer Drug Patent
The Federal Circuit on Tuesday upheld a Patent Trial and Appeal Board decision invalidating a patent on Johnson & Johnson's blockbuster prostate cancer drug Zytiga, while leaving open a larger question...To view the full article, register now.
Already a subscriber? Click here to view full article